Equity Research on Gilead Sciences Inc. and Human Genome Sciences Inc. - Regulatory Approval Key for Biotech Companies
October 06 2011 - 8:15AM
Marketwired
www.shinesrooms.com has a handpicked team of market professionals
with over 100 years of combined investing experience. Today they
are providing members comprehensive research on the Biotechnology
industry and are offering free analytical research on
Gilead Sciences Inc. (NASDAQ: GILD) and
Human Genome Sciences Inc. (NASDAQ: HGSI). Register
with us today at
http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index.com
to have free access to these research reports.
Drug approvals from administrative bodies in both the U.S. and
Europe have been pivotal for biotech companies recently. Investors
have been particularly sensitive to decisions made on new drugs
considering the state of the global economic recovery. Get your
free reports on Gilead Sciences Inc. and
Human Genome Sciences Inc. at
http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index.
There is no commitment to join.
www.shinesrooms.com is the Ultimate Trading Environment for
investors. If you are considering owning Gilead Sciences Inc. and
Human Genome Sciences Inc. then you should sign up for a free
membership and our complimentary reports today at
www.shinesrooms.com. Over the last 5 years our returns outpaced any
of the major indexes. Sign up today to find out what you are
missing.
The Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency gave a positive recommendation for
Eviplera, a combination of Gilead Sciences Inc.'s Truvada and
Johnson and Johnson's Edurant, for the treatment of HIV in
previously untreated adults. The recommendation bodes very well for
European approval when the EMA will make its decision later in the
year. Gilead Sciences Inc. report is
accessible for free by registering today at
http://www.shinesrooms.com/GileadSciencesInc061011.pdf.
Human Genome Sciences Inc. has not been as fortunate recently.
British regulators chose not to approve the company's lupus drug,
Benylsta, for national coverage. The drug had previously seen
positive sales in the U.S. though. Human Genome
Sciences Inc. report is accessible for free by registering
today at
http://www.shinesrooms.com/HumanGenomeSciencesInc061011.pdf.
Overall, investors appear particularly sensitive to regulatory
decisions on new drugs. Companies receiving approvals could see
share prices climb while negative decisions may do just the
opposite.
The two Biotechnology stocks research
reports are available for free by signing up now on
www.shinesrooms.com.
About Shinesrooms.com
Shine's Rooms is the brain child of David Shine, a 13 year Wall
Street veteran with a stellar track record. For 13 years Shine has
trained thousands of traders to navigate and profit from the
markets. Using cutting edge technology, Shine provides you with a
community in which you can trade alongside Shine and his Team as
they guide you through the market's ever-changing landscape.
To view our disclaimer, visit this link
http://www.shinesrooms.com/disclaimer.html.
Contact Person: Michael Thomas Smith Marketing
Coordinator info@shinesrooms.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024